TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05155436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
Description: Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.
Study: NCT06165705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: dichoptic therapy with anaglyph goggles and eye tracking
Study: NCT05450289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa Oil
Description: In this study, we use nigella sativa oil (NSO), which are packed in capsule. One capsule contained 550 mg of nigella sativa oil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Specific Immunotherapy
Description: In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allergen Specific Immunotherapy
Description: In this study, we use the house dust mite allergen immunotherapy (Teaching Industry Allergen by Dr. Soetomo Hospital-Airlangga University, Surabaya, Indonesia) used was an extract of Dermatophagoides pteronyssinus via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard pharmacotherapy
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard pharmacotherapy
Description: Standard pharmacotherapy as indicated based on patient's symptoms i.e none, antihistamine, corticosteroids, bronchodilators, etc.
Study: NCT05795699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: K-321 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study: NCT06663579

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fathers who practicing kangaroo care
Description: The study group (n=28) It consists of fathers of babies practicing Kangaroo Care with both their mothers and fathers in the neonatal intensive care unit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fathers who not practicing kangaroo care
Description: The control group (n=28) It consists of fathers of babies practicing Kangaroo Care with their mothers in the neonatal intensive care unit.
Study: NCT06663839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological NILK-2301
Description: Treatments will be administered every two weeks in 28-day cycles for up to 12 months until disease progression, unacceptable toxicity, or Investigator/patient decision to withdraw study consent. Should evidence emerge showing that treatment beyond one year may prolong benefit in responding patients, the protocol will be amended to ensure that these responding patients may continue with the study treatment beyond 12 months until disease progression.
Study: NCT06664658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peep 5
Description: he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peep 10
Description: he patients included in the study were divided into 2 groups. Among the patients who were going to be operated, 5 PEEP were applied to Group I (n=30) cases, and 10 PEEP to Group II (n=30) cases during ventilation with anesthesia device. All patients were evaluated by transthoracic lung ultrasonography before anesthetic induction, after tracheal intubation, after pneumoperitoneum, and 15 minutes after recovery from anesthesia. According to the lung USG protocol, a total of 6 regions, including 2 quadrants of each hemi-thorax anterior wall, 2 right and left lateral walls, and 2 quadrants of the posterior wall, a total of 12 regions in each patient were scanned, and the images were evaluated. According to the modified lung USG scoring system, each region was scored between 0-3 consistent with the degree of atelectasis
Study: NCT06664398

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one HIIT
Description: one HIIT high intensity interval training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: four HIIT
Description: four HIIT high intensity interval training
Study: NCT05568394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy combinded with therapeutic exercise
Description: The treatment includes cervical mobilization and specific therapeutic exercises: craniocervical and cervical flexors and extensors, axioscapular muscles, and postural correction (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: The treatment includes routine physical therapy (e.g., modalities, range of motion and/or gentle stretching exercise) (30-40 minutes).~The participants will attend 20 individual treatment sessions (2 visits per week for 10 weeks).
Study: NCT06612086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (Forxiga)
Description: we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient
Study: NCT06611436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 dose from Dose Level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BE-101
Description: IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation
Study: NCT06318299

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester
Description: Commercially available ketone ester drink (KetoneAid, Virginia, USA)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone Ester
Description: Commercially available ketone ester drink (KetoneAid, Virginia, USA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taste and appearance matched noncaloric placebo drink
Study: NCT04286347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HCV, HBV, HIV tests
Description: HCV, HBV, HIV testing during consultation with Anesthesiologist before a planned surgery
Study: NCT05584449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Attend online group facilitated by two oncology social workers

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Discuss survivorship issues/concerns

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive young adult cancer survivorship information

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06369740

Intervention type: OTHER
Intervention: Case scenarios - questionnaire
Description: Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.

Intervention type: OTHER
Intervention: Case scenarios - questionnaire
Description: Participants fill in a questionnaire on the current care of hemophilia A and envisioned use scenarios of a point-of-care diagnostic device for hemophilia A.

Intervention type: OTHER
Intervention: Case scenarios - Focus groups
Description: Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.

Intervention type: OTHER
Intervention: Case scenarios - Focus groups
Description: Participants partake in focus groups on the current care for hemophilia A, the envisioned use scenarios of point-of-care diagnostic device for hemophilia A and desired features of such a diagnostic device.

Intervention type: OTHER
Intervention: Use scenarios - Usability test
Description: Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).

Intervention type: OTHER
Intervention: Use scenarios - Usability test
Description: Participants are asked to perform basic tasks with the mock-ups with minimal instructions, they will also be given a graphic of the user interface (GUI).

Intervention type: OTHER
Intervention: Use scenarios - interview
Description: The participants will be interviewed and asked for their opinions and experiences with the mock-ups.

Intervention type: OTHER
Intervention: Use scenarios - interview
Description: The participants will be interviewed and asked for their opinions and experiences with the mock-ups.
Study: NCT06005259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone 25 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT04865822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single session pain education class
Description: Pain education classes will be provided in person group or virtual settings
Study: NCT05581368

Intervention type: OTHER
Intervention: Chronic Cannabis use
Description: The investigators will test levels of inflammation and vascular dysfunction in participants who chronically use cannabis.
Study: NCT06428097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo will be normal saline and will be dosed at the same rate and time as the study drug.
Study: NCT05897359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bCBTMI
Description: This experimental group involves 4 weekly 30-45 minute sessions using the brief CBT and the brief MI models by trained nursing students.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive health talks about internet addiction consequences and impacts on young people by nursing students who are not involved in the intervention group to mimic the time and attention spent on the intervention group. These health talks are considered routine care for IA health promotion.
Study: NCT05250609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endocrown composite.
Description: It is a type of restoration has been shown a great success in adult and recently has been suggested for children
Study: NCT04931134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation - active
Description: Active trigeminal nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trigeminal nerve stimulation - sham
Description: Sham trigeminal nerve stimulation
Study: NCT04726982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 250 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: 500 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT05482347

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational video
Description: The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: The intervention is an educational video developed using data from focus groups of families with children diagnosed with neurogenic bladder.
Study: NCT05226104

Intervention type: DEVICE
Group type: OTHER
Intervention: MOXI
Description: Patients will receive treatment using f1927 devices and will be treated twice over the affected areas, once each month for a total of two months.
Study: NCT04770805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetoscopy
Description: After an exteriorization of the uterus through a laparotomy, humidified and warmed gas will be insufflated with low pressure (6 to 8mmHg mmHg). Fetoscopic repair surgery will consist in a dissection of the placode, its reintegration into the spinal canal and the closure of the lesion, through a three ports access. After fetal surgery, the gas will be exsufflated and the trocar ports will be closed. The uterus will be reintegrated before suturing the maternal abdominal wall.
Study: NCT05745740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib 400 mg by oral once a day.
Study: NCT05251233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules contain pharmaceutical-grade lactose monohydrate NF, a naturally occurring disaccharide of galactose bound to glucose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: The study will use commercial supply.
Study: NCT04788732

Intervention type: DEVICE
Intervention: ECG and EEG monitoring
Description: the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.

Intervention type: DEVICE
Intervention: ECG and EEG monitoring
Description: the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.

Intervention type: DEVICE
Intervention: ECG and EEG monitoring
Description: the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
Study: NCT05794555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Patients will be prescribed lactulose and will also receive enhanced usual care. Lactulose will be taken on a specific schedule based on the average number of bowel movements on average per day. It will be started at 15 milliliter (mL) dose and will be instructed to slowly increase the lactulose dose over the course of the first week of Stage 1 participation. The prescribed maximum dose will be 30 mL (20g) twice daily. The dose will slowly increase toward the maximum or until participants reach 2-3 soft bowel movements daily.~Participants that receive Lactulose during stage 1 will continue this in stage 2.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Investigator recommended exercise
Description: Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Investigator recommended exercise
Description: Participants randomized to enhanced usual care will be reminded of standard fall precautions outlined in the Fall Prevention Primer that were provided in Stage 1 and will receive exercise recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleTai-Chi (virtual)
Description: TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.
Study: NCT05751135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration
Description: Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration
Description: Focal muscle vibration will be provided by a longitudinal muscle vibrator on muscles of lower limb; hamstrings, quadriceps, illiopsoas, calf, gluteus maximus and medius. Each muscle will be targeted 3 times with 30 seconds time period and keeping 10 second interval.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Stretching of shortened lower extremity muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching of shortened lower extremity muscle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching of shortened lower extremity muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening
Description: Strengthening exercises for weak lower extremity muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening exercises for weak lower extremity muscles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening
Description: Strengthening exercises for weak lower extremity muscles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning
Description: Positioning of participant to maintain a good body posture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Positioning of participant to maintain a good body posture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning
Description: Positioning of participant to maintain a good body posture
Study: NCT04895397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Nerve Block procedure
Description: In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Nerve Block procedure
Description: In group A patients, an ultrasound guided modified pectoral nerve block will be performed Under sterile conditions, US-guided PECSII block will be on the same side of surgery . The 6-13 MHz linear probe will be put transversely in the ipsilateral clavipectoral triangle - between the clavicle medially and above and the shoulder joint laterally.~the needle will be advanced in an in-plane technique targeting the space in which the artery is located. Afterward, 10 mL of bupivacaine, 0.25%, will be injected.~the needle will be advanced in-plane targeting the plane between the pectoralis minor muscle and serratus. Two mL of saline 0.9% will be injected; then, 10 mL of bupivacaine 0.25% will be injected.~Group B: In SAPB Group, a US-guided serratus block will be done The ribs will be then counted, and when the 4th rib will be identified, the high-frequency probe will be put over it, in the mid-axillary line in a sagittal plane.
Study: NCT05794555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleTai-Chi (virtual)
Description: TeleTai-Chi will be taught remotely via live Zoom classes of up to 15 patients by a certified TeleTai-Chi instructor three times per week (for approximately 12 weeks). Classes will be conducted via a HIPAA-compliant Zoom server through the University of Michigan. Participants will be instructed to use Zoom by smartphone, tablet, or computer. High-Definition Multimedia Interface (HDMI) cables and other device specific equipment to connect devices to televisions will be provided.